Clinical Trial Detail

NCT ID NCT02014636
Title Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

renal cell carcinoma

Therapies

Pazopanib

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.